When was Novartis founded?

Novartis was founded in 1996 and raised its 1st funding round 12 years after it was founded.

Where is Novartis located?

Novartis is headquartered in Basel, Switzerland. It is registered at Inspire BKC 7th Floor Bandra Kurla Complex, Bandra East, Bandra(East), Mumbai, Bandra, Maharashtra, India, 400051.

How many employees does Novartis have?

As of Sep 30, 2026, the latest employee count at Novartis is 85209.

Is Novartis a funded company?

Novartis is a funded company, having raised an undisclosed amount across 19 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on Aug 26, 2008.

When was the latest funding round of Novartis?

Novartis' latest funding was a $***** Grant (prize money) round on Dec 01, 2018, with participation from 1 investor.

What is the annual revenue of Novartis?

Annual revenue of Novartis is less than $1M as on Dec 31, 2017

Where does Novartis rank among its competitors?

Novartis ranks 8th amongst 2335 active competitors, of which 141 are funded. It stands 9th in terms of total funding among its competitors. The most recent competitor to raise funding was AstraZeneca, which secured $6.05M in Jul, 2025.

Who are the top competitors of Novartis?

Novartis' top competitors include AbbVie, Gilead and Amgen. Among them, AstraZeneca secured the most recent funding round in July, 2025.

Novartis - 2026 Company Profile, Team, Funding, Competitors & Financials

Novartis is an acquired company based in Basel (Switzerland), founded in 1996 by Robin Roberts, Biswajit Kumar and Stefan Tügend. It operates as a R&D focused on manufacturing of drugs for multiple therapeutic areas. Novartis has raised an undisclosed amount in funding. The company has 2335 active competitors, including 141 funded and 259 that have exited. Its top competitors include companies like AbbVie, Gilead and Amgen.

Company Details

R&D focused on manufacturing of drugs for multiple therapeutic areas. The Company segments include Pharmaceuticals, which researches, develops, manufactures, distributes, and sells prescription medicines in the therapeutic areas, such as oncology, cardio-metabolic, immunology and dermatology, retina, respiratory, neuroscience, and established medicines; Alcon, which operates through over three franchises Surgical, Ophthalmic Pharmaceuticals and Vision Care, and Sandoz, which develops, manufactures and markets generic pharmaceutical products, follow-on biopharmaceutical products known as biosimilars, and other drug substances.

Website: www.novartis.com/
Social
Email ID: *****@novartis.com
Phone Number: +41 **********
Registered Address: Inspire BKC 7th Floor Bandra Kurla Complex, Bandra East, Bandra(East), Mumbai, Bandra, Maharashtra, India, 400051

Key Metrics

Founded Year

1996

Location

Basel, Switzerland

Stage

Acquired

Latest Funding Round

Grant (prize money), Dec 01, 2018, $*****

Investors

Digital Pharma Lab & 10 more

Ranked

8^th among 2335 active competitors

Annual Revenue

$0 - $1M as on Dec 31, 2017

Employee Count

85,209 as on Sep 30, 2026

Investment & Acquisitions

Myricx Bio & 163 more

Similar Companies

AbbVie & 2418 more

Exit Details

Acquired by ChrysCapital (Feb 21, 2026)

View Novartis' full profile

Novartis is associated with 5 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
NOVARTIS HEALTHCARE A/S CIN: 20575786 , Denmark, Active	Dec 16, 1997	-	97 (As on Apr 30, 2024)
NOVARTIS HRVATSKA D.O.O. CIN: 70166062414 , Croatia, Active	Mar 20, 2005	$10M - $50M (As on Dec 31, 2014)	-
Endocyte Inc CIN: 1235007 , United States, Active	Dec 10, 2001	$0 - $1M (As on Dec 31, 2017)	-	-
NOVARTIS INDIA LIMITED CIN: L24200MH1947PLC006104 , India, Active	Dec 13, 1947	₹100 - ₹500 Cr (As on Mar 31, 2025)	53 (As on Mar 01, 2026)
NOVARTIS HEALTHCARE PRIVATE LIMITED CIN: U15202MH1997PTC111257 , India, Active	Oct 13, 1997	₹1,000+ Cr (As on Mar 31, 2025)	7534 (As on Feb 29, 2024)

Novartis got acquired by ChrysCapital on Feb 21, 2026.

Click here to take a look at Novartis's acquisition in detail

Novartis has raised funding over 19 rounds. Its first funding round was on Aug 26, 2008. Its latest funding round was a Grant (prize money) round on Dec 01, 2018 for $*****. 1 investor participated in its latest round. Novartis has 11 institutional investors.

Here is the list of recent funding rounds of Novartis:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Dec 01, 2018	3892238	Grant (prize money)	7857644	3410753	8018692	6331771
Jun 01, 2018	4684827	Grant (prize money)	5020918	1239699	2969302	Europa
Jul 01, 2017	9329379	Grant (prize money)	9997416	1937309	6311230	Europa

Access funding benchmarks and valuations. Sign up today!

View details of Novartis's funding rounds and investors

The founders of Novartis are Robin Roberts, Biswajit Kumar and Stefan Tügend.

Here are the details of Novartis' key team members:

Robin Roberts: Founder/ Head - Global Trial Budget Management, Global Drug Development of Novartis.
Biswajit Kumar: Group Lead/Head- Database Operations (Co-founder- internal GBS Biometrics organization) of Novartis.
Stefan Tügend: Co-Founder and Lead BeMindful! Employee Resource Group of Novartis.

View details of Novartis's Founder profiles and Board Members

Novartis' employee count trend

Novartis has 85,209 employees as of Sep 26. Here is Novartis's employee count trend over the years:

Uncover Novartis' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Novartis include AbbVie, Gilead and Amgen. Here is the list of Top 10 competitors of Novartis, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	AbbVie 2012, Chicago (United States), Public	Research-based biopharmaceutical company	$14.7B	Berkshire Hathaway, Alcor Fund & 10 others	83/100
2nd	Gilead 1987, Foster City (United States), Acquired	Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others	-	BB Biotech, Jindal Ventures & 17 others	81/100
3rd	Amgen 1980, Thousand Oaks (United States), Public	Developer of pharmaceutical products for treating multiple diseases	-	Digital Pharma Lab, Amgen Business Development ... & 11 others	79/100
4th	AstraZeneca 1999, Cambridge (United Kingdom), Public	Developer of pharmaceutical medicines for oncology and various chronic diseases	-	Digital Pharma Lab, Columbia Capital & 13 others	76/100
5th	Lilly 1876, Indianapolis (United States), Public	Developer of traditional pharmaceutical medicines	-	Alcor Fund, Digital Pharma Lab & 11 others	75/100
6th	Johnson & Johnson 1886, New Brunswick (United States), Public	Manufacturer and supplier of beauty care products, medical devices, and pharmaceutical products	-	Western Technology Investment, Alcor Fund ... & 17 others	75/100
7th	Roivant Sciences 2014, New York City (United States), Public	Developer of therapeutics to treat neurology, oncology, rare, and endocrinology based diseases	$1.3B	SoftBank Vision Fund, NovaQuest Capital Management ... & 8 others	71/100
8th	Novartis 1996, Basel (Switzerland), Acquired	R&D focused on manufacturing of drugs for multiple therapeutic areas	-	Digital Pharma Lab, Atlas Venture & 9 others	72/100
9th	Roche 1896, Basel (Switzerland), Public	Developer of pharmaceuticals and diagnostics kits	-	Gilde Healthcare, SoftBank Group & 11 others	70/100
10th	Genentech 1976, San Francisco (United States), Acquired	R&D company focused on manufacturing drugs for multiple therapeutic areas	$72.5M	Ignite 500, The Column Group & 4 others	68/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on Novartis's competitors? Click here to see the top ones

Novartis has made 120 investments in companies including Flare Therapeutics and NRG Therapeutics. Novartis has also acquired 44 companies including Myricx Bio and Excellergy.

Here is the list of investments & acquisitions:

Filter this list

Date of Investment/Acquisition	Type	Company Name	Founded Year	Location
Jul 06, 2026	Acquisition	Myricx Bio	2019	London (United Kingdom)
Jun 30, 2026	Investments	Flare Therapeutics	2021	Cambridge (United States)
Mar 27, 2026	Acquisition	Excellergy	2020	Palo Alto (United States)